Abstract
Genetic Engineering & Biotechnology NewsVol. 42, No. 5 DepartmentsWhy We Need an Alzheimer's Moonshot in 2022Genuv calls for an urgent, all-hands-on-deck drug development effort to ameliorate the fast-worsening health crisis that is Alzheimer's diseaseSungho Han, PhD and Allan I. Levey, MD, PhDSungho Han, PhDSungho Han, PhD, is founder and CEO of Genuv, a clinical-stage biopharma company in Seoul, South Korea, that develops treatments for cancer and degenerative neurological diseases. Allan I. Levey, MD, PhD, is a neurologist and neuroscientist at the Emory University School of Medicine who advises Genuv. Website: https://genuv.com.Search for more papers by this author and Allan I. Levey, MD, PhDSungho Han, PhD, is founder and CEO of Genuv, a clinical-stage biopharma company in Seoul, South Korea, that develops treatments for cancer and degenerative neurological diseases. Allan I. Levey, MD, PhD, is a neurologist and neuroscientist at the Emory University School of Medicine who advises Genuv. Website: https://genuv.com.Search for more papers by this authorPublished Online:10 May 2022https://doi.org/10.1089/gen.42.05.06AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 42Issue 5May 2022 Information© 2022 by GEN PublishingTo cite this article:Sungho Han, PhD and Allan I. Levey, MD, PhD.Why We Need an Alzheimer's Moonshot in 2022.Genetic Engineering & Biotechnology News.May 2022.18-19.http://doi.org/10.1089/gen.42.05.06Published in Volume: 42 Issue 5: May 10, 2022PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
